Gastroenterological disorders increase the prevalence of overactive bladder in females at various ages

Yıl 2022, , 84 - 87, 17.01.2022

Sedat Taştemur , Şenol Tonyalı , Buğra Bilge Keseroğlu , Mercan Taştemur Mustafa Karaaslan , Bayram Yeşil Mahmut Yüksel

https://doi.org/10.32322/jhsm.977632

Öz

Aim: In this study we aimed to determine the coexistence of overactive bladder in patients with gastroenterological disorders including hepatitis, cirrhosis and inflammatory bowel disease (IBD).
Material and Method: We prospectively collected the data of patients who admitted to the outpatient clinic of department of gastroenterology at Ankara Yüksek İhtisas Training and Research Hospital between May 2017 and February 2019. All patients with chronic gastroenterological disorders such as hepatitis and irritable bowel syndrome willing to participate after the verbal consent were included in the study
Results: A total of 289 female patients were included the study. The mean age of the patients was 49.9 ±13 years. The mean BMI value was 27.9± 4.5 kg/m2. Among 289 patients, 135 (46.7%) had Hepatitis B, 53 (18.3%) had ulcerative colitis, 35 (12.1%) had Crohn’s disease, 22 (7.6%) had autoimmune hepatitis, 19 (6.6%) had primer biliary cirrhosis, 13 (4.5%) had Hepatitis C and 12(4.2%) had celiac disease. The mean age of patients was similar between patients having OAB-v8 higher and lower than 8 (p=0.46). However, patients having OAB score>8 had higher BMI compared to patients who had OAB score <8, 29.1 ±5 vs. 27.2 ±4.1 kg/m2, p=0.001. In multivariate regression analysis, BMI was the sole indicator of OAB (p=0.001) whereas age (p=0.46), menopause status (p=0.33), smoking status (p=0.97) were not.
Conclusion: The incidence of OAB in our patient cohort was higher than the reported incidence by that evaluating the patients with gastrointestinal disorders in terms of overactive bladder on routine follow-up might be suggested.

Anahtar Kelimeler

Gastroenterological disorders, OAB-v8, Overactive bladder

Kaynakça

• Gormley EA, Lightner DJ, Faraday M, and Vasavada SP; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193: 1572-80.
• Jaffe WI and Te AE; Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005; 6: 410-8.
• Sales-Campos H, Basso PJ, Alves VBF, et al. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian J Med Biol Res 2015; 48: 96-107.
• Karabay EA, Küçükünal NA, Altunay IK, Çerman AA, Alkim C. Gastroenteroloji kliniginde yatan hastalarda izlenen deri bulguları/Skin findings of patients hospitalised in the gastroenterology department. Şişli Etfal Hastanesi Tip Bülteni 2016; 50: 273.
• Burisch J, Jess T, Martinato M, and Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohn's and Colitis 2013; 7: 322-37.
• Uzun H, Oğullar S, Ünal H, Zorba OÜ, Yazar S, Kalkan M. Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women. Scandinavian J urol 2013; 47: 497-502.
• Cetin EG, Demir N, and Sen I. The relationship between insulin resistance and liver damage in non-alcoholic fatty liver patients. Med Bull Sisli Etfal Hospital 2020; 54: 411.
• Tarcan T, Mangir N, O’zgur M, Akbal C. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni 2012; 21: 113-6.
• Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005; 22: 381-94.
• Tomaszewski J. Postmenopausal overactive bladder. Przeglad Menopauzalny= Menopause Rev 2014; 13: 313.
• Kawahara T, Ito H, Yao M, Uemura H. Impact of smoking habit on overactive bladder symptoms and incontinence in women. Int J Urol 2020; 27: 1078-86.
• Sarikaya K, Senocak C, Sadioglu FE, Ciftci M, Bozkurt OF. Comparison of long-term outcomes of transobturator rectus fascia sling and polypropylene mesh in obese women? J Gynecol Surg 2021; 37: 246-51.
• Brumovsky PR and Gebhart GF. Visceral organ cross-sensitization — an integrated perspective. Autonomic Neurosci 2010; 153: 106-15.
• Whorwell PJ, McCallum M, Creed FH, and Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986; 27: 37-40.
• Grundy L, Brierley SM. Cross-organ sensitization between the colon and bladder: to pee or not to pee? Am J Physiol Gastrointest Liver Physiol 2018; 314: 301-8.
• Ben-Ami H, Ginesin Y, Behar DM, Fisher D, Edoute Y, Lavy A. Diagnosis and treatment of urinary tract complication in Crohn’s disease: an experience over 15 years. Can J Gastroenterol 2002; 16: 225-9.
• Xia C, Shen S, Hashmi F, and Qiao L-Y. Colitis-induced bladder afferent neuronal activation is regulated by BDNF through PLCγ pathway. Exper Neurol 2016; 285: 126-35.
• Pezzone MA, Liang R, and Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterol 2005; 128: 1953-64.
• Matsumoto S, Hashizume K, Wada N, et al. Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int 2013; 111: 647-52.
• Kim KS, Kim HJ, Lee SH, Cho ST, and Moon HS. Association between irritable Bowel syndrome and overactive bladder: a research survey. Urology 2017; 109: 88-93.